160 related articles for article (PubMed ID: 9720739)
1. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Simpson DR; Nevill TJ; Shepherd JD; Fung HC; Horsman DE; Nantel SH; Vickars LM; Sutherland HJ; Toze CL; Hogge DE; Klingemann HG; Naiman SC; Barnett MJ
Bone Marrow Transplant; 1998 Aug; 22(3):259-64. PubMed ID: 9720739
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
8. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
9. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
[TBL] [Abstract][Full Text] [Related]
12. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
14. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
16. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
19. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Ayas M; Al-Seraihi A; Al-Mahr M; Al-Jefri A; Belgaumi A; Elhassan I; El-Solh H
Pediatr Blood Cancer; 2006 Dec; 47(7):926-30. PubMed ID: 16425264
[TBL] [Abstract][Full Text] [Related]
20. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
